Vineet Laborator (VINEETLAB)
Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹37.29 |
| Market Cap | ₹71.62 Cr |
| P/E Ratio | 0 |
| ROCE | -27.95% |
| ROE | -32.96% |
| Dividend Yield | 0% |
| Profit Growth | 114.89% |
| Debt/Equity | 3.01 |
| Sales Growth | -13.4% |
| Promoter Holding | 5.98% |
| 52-Week Range | ₹27.96 — ₹49.99 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹15.25 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At ₹41.45, Vineet Laborator is a ₹57 Cr micro-cap with a book value of ₹34.64 per share, so the price is 1.20 times book. In ordinary circumstances that looks reasonable, but Graham taught us to look through the balance sheet to earning power. Here earning power is missing: ROE is -32.96% and ROCE is -27.95%. The company is destroying capital. Sales have fallen by 13.54%, and debt-to-equity stands at 3.01, a stretched balance sheet for a small pharmaceutical business. There is no dividend; the P/E is meaningless because annual earnings are near zero.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer